Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Biodefense Partners Charged With Fighting Disease as Weapon
Uncategorized

Biodefense Partners Charged With Fighting Disease as Weapon

By medwebOct 1, 2005
Share
Facebook Twitter Email

October 25, 2005

Biodefense Partners Charged with Fighting Disease as Weapon

CHICAGO—Northwestern University has been named a collaborating institution for a Regional Center of Excellence (RCE) for Biodefense and Emerging Diseases by the National Institute of Allergy and Infectious Diseases (NIAID).

Robert L. Murphy, MD, John Philip Phair Professor of Infectious Diseases and professor of medicine at the Feinberg School of Medicine, will head the center with principal investigator Olaf Schneewind, MD, PhD, of the University of Chicago.

The five-year, $35 million collaborative effort, which involves researchers from lead institution University of Chicago, Argonne National Laboratory, and 20 additional upper-Midwest universities, hospitals, and research organizations, will apply the tools of modern science to fight infectious diseases, with particular emphasis on those that can be used as biological weapons and for emerging or newly identified microbial pathogens.

The NIAID plans to invest approximately $350 million over five yeas in eight such centers around the country.

The regional centers are a key element in the NIAID’s strategic plan to expand research in the detection, prevention, and treatment of potentially lethal illnesses that can be caused by biological agents ranging from the known pathogens that could be used for bioterrorism to new and as yet little-known emerging diseases that develop naturally, such as SARS, West Nile virus, drug-resistant bacteria, and many others.

The Great Lakes RCE will focus on the development of diagnostic, therapeutic, and vaccine products for anthrax, botulism, tularemia, hemorrhagic fever viruses, and plague. Such research, based on genomics, proteomics, and a molecular-level understanding of cell function, is expected to have profound and far-reaching consequences during the next decade and beyond.

“The strength of the Great Lakes RCE is in the quality and diversity of its member institutions and scientists,” Dr. Murphy said.

“Together we will be able to pool our resources and develop novel diagnostic tests, vaccines, and treatment against the agents of bioterrorism and emerging infections,” Dr. Murphy said.

The Great Lakes RCE will join together research groups from 22 institutions in six states included in federally designated Region V.

The research teams will involve more than 300 scientists, said Dr. Murphy, including a core of more than 60 key researchers who specialize in microbiology, immunology, infectious diseases, public health, medicine, vaccine research, and pharmacology, as well as related disciplines such as biochemistry, computer science, engineering, mathematics, and nanotechnology.

Besides performing research, the RCE will act as a regional resource for public health officials, providing expertise, rapid diagnosis, support, and advice about containment and treatment in the event of a bioterror outbreak or the emergence of new disease-causing agents. It also will teach young scientists and technicians how to conduct productive and safe research on infectious diseases.

Share. Facebook Twitter Email

Related Posts

Lurie Cancer Center Receives Merit Extension from NCI

Oct 20, 2021

Drug Combination May Reduce Risk of Leukemia Relapse

Mar 26, 2020

Rewriting the Role of a Transcription Factor

Mar 19, 2020

Comments are closed.

Latest News

Celebrating Feinberg’s 2023 Match Day

Mar 17, 2023

Predicting Risk of Blood Clots in Brain Tumors

Mar 16, 2023

Understanding How Exercise Induces Systemic Metabolic Benefits

Mar 15, 2023

Future Directions in Continuing Medical Education

Mar 14, 2023

Lieber Receives VA Rehabilitation Research and Development Award 

Mar 13, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
_5NM1245
230204_SERIO_MANDELL_Feinberg_Formal_0928
_5NM1715
_5NM0526
_5NM1026 (1)
_5NM1906
_5NM2173
230204_SERIO_MANDELL_Feinberg_Formal_0896
230204_SERIO_MANDELL_Feinberg_Formal_1113
230204_SERIO_MANDELL_Feinberg_Formal_1868
230204_SERIO_MANDELL_Feinberg_Formal_1237
230204_SERIO_MANDELL_Feinberg_Formal_1172

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.